Anavex Life Sciences Corp (AVXL)

[falconer66a]

No problems with blarcamesine information or sales. Easy.

Anavex will sign up with one of the major drug distribution companies and that issue will be solved. Word of mouth is the best and cheapest form of advertising.

Exactly.

Anavex will have no problems gaining distribution channels for their drugs, nor for getting useful info into the heads of either physicians or patients or care-givers.

In regard to the later, once successful clinical results, for Rett, Parkinson’s disease dementia (PDD), and Alzheimer’s appear, in each case they will generate big news articles. The stories for Rett will be moderate, only because few people have ever heard of the disease. But, it’s a CNS disease, and blarcamesine will successfully treat it.

How will the press tell about blarcamesine stopping, even reversing PDD? A whopper of a story, a drug stopping some form of dementia, in a form of Parkinson’s. Everyone’s heard of dementia and Parkinson’s. Anavex and blarcamesine become well-known, and fully appreciated.

Then, finally, of course, Alzheimer’s. Nothing more need be said.

The demand for blarcamesine therapies will be in the millions. Anavex needs merely to ship stocks of blarcamesine to all of the national pharmacy chains. Physicians will write prescriptions and patients will take mailed-out orders of the drugs, or just drive over to the pharmacy and pick up the pills.

Physicians will have read the in-depth PDF info booklets on blarcamesine provided by Anavex.

Nothing more complicated than that.